Blood Pressure Targets Recommended by Guidelines and Incidence of Cardiovascular and Renal Events in the Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial

The following are highlights from the new series, Circulation: Cardiovascular Quality and Outcomes Topic Review. This series will summarize the most important manuscripts, as selected by the Editor, which have published in the Circulation portfolio. The objective of this new series is to provide our readership with a timely, comprehensive selection of important papers that are relevant to the quality and outcomes, as well as general cardiology audience. The studies included in this article represent the most significant research related to hypertension.

[1]  E. O’Brien,et al.  Prognostic significance of visit-to-visit variability, maximum systolic blood pressure, and episodic hypertension , 2010, The Lancet.

[2]  B. Egan,et al.  US trends in prevalence, awareness, treatment, and control of hypertension, 1988-2008. , 2010, JAMA.

[3]  F. Turnbull.  Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials , 2003, The Lancet.

[4]  M. Mack,et al.  Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document. , 2012, Journal of the American College of Cardiology.

[5]  Daniel W. Jones,et al.  Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. , 2003, Hypertension.

[6]  Avis J. Thomas,et al.  Lifetime risks of cardiovascular disease. , 2012, The New England journal of medicine.

[7]  A. Rodgers,et al.  Global burden of blood-pressure-related disease, 2001 , 2008, The Lancet.

[8]  G. Bray,et al.  Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet , 2001 .

[9]  Marco Valgimigli,et al.  Standardized Bleeding Definitions for Cardiovascular Clinical Trials: A Consensus Report From the Bleeding Academic Research Consortium , 2011, Circulation.

[10]  Jiang He,et al.  Effect of Aerobic Exercise on Blood Pressure , 2002, Annals of Internal Medicine.

[11]  G. Mancia,et al.  Calcium Antagonist Lacidipine Slows Down Progression of Asymptomatic Carotid Atherosclerosis: Principal Results of the European Lacidipine Study on Atherosclerosis (ELSA), a Randomized, Double-Blind, Long-Term Trial , 2002, Circulation.

[12]  J. Coresh,et al.  Prevalence of high blood pressure and elevated serum creatinine level in the United States: findings from the third National Health and Nutrition Examination Survey (1988-1994). , 2001, Archives of internal medicine.

[13]  J. Selby,et al.  TRIALS STUDY PROTOCOL Open Access Study protocol: The Adherence and , 2022 .

[14]  A. Dyer,et al.  Impact of Blood Pressure and Blood Pressure Change During Middle Age on the Remaining Lifetime Risk for Cardiovascular Disease: The Cardiovascular Lifetime Risk Pooling Project , 2012, Circulation.

[15]  D. Jacobs,et al.  Trends in Blood Pressure and Hypertension Detection, Treatment, and Control 1980 to 2009: The Minnesota Heart Survey , 2012, Circulation.

[16]  P. Cosgrove,et al.  Cost-Effectiveness of Community-Based Strategies for Blood Pressure Control in a Low-Income Developing Country: Findings From a Cluster-Randomized, Factorial-Controlled Trial , 2011, Circulation.

[17]  Ronald E. Jones,et al.  Blood Pressure Control Among US Veterans: A Large Multiyear Analysis of Blood Pressure Data From the Veterans Administration Health Data Repository , 2012, Circulation.

[18]  Daniel W. Jones,et al.  Effect of dietary protein supplementation on blood pressure: a randomized, controlled trial. , 2011, Circulation.

[19]  M. Järvelin,et al.  Elevated Blood Pressure in Pregnancy and Subsequent Chronic Disease Risk , 2013, Circulation.

[20]  J. Geleijnse,et al.  Dietary Protein and Blood Pressure: A Systematic Review , 2010, PloS one.

[21]  Alan D. Lopez,et al.  A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010 , 2012, The Lancet.

[22]  R. Aungst,et al.  Healthy People 2020 , 2013, American Journal of Kidney Diseases.

[23]  S. Bangalore,et al.  Blood Pressure Targets in Subjects With Type 2 Diabetes Mellitus/Impaired Fasting Glucose: Observations From Traditional and Bayesian Random-Effects Meta-Analyses of Randomized Trials , 2011, Circulation.

[24]  Rob Baltussen,et al.  Making Choices in Health: WHO Guide to Cost Effectiveness Analysis , 2003 .

[25]  P. Rothwell,et al.  Effects of antihypertensive-drug class on interindividual variation in blood pressure and risk of stroke: a systematic review and meta-analysis , 2010, The Lancet.

[26]  Yan-jun Xu,et al.  Prevalence, Awareness, Treatment, and Control of Hypertension Among Residents in Guangdong Province, China, 2004 to 2007 , 2013, Circulation. Cardiovascular quality and outcomes.

[27]  Rod Jackson,et al.  Treatment with drugs to lower blood pressure and blood cholesterol based on an individual's absolute cardiovascular risk , 2005, The Lancet.

[28]  E. Peterson,et al.  Hypertension Control Among Patients Followed by Cardiologists , 2012, Circulation. Cardiovascular quality and outcomes.

[29]  W. Elliott.  US Trends in Prevalence, Awareness, Treatment, and Control of Hypertension, 1988-2008 , 2011 .

[30]  E. Ford.  Trends in Mortality From All Causes and Cardiovascular Disease Among Hypertensive and Nonhypertensive Adults in the United States , 2011, Circulation.

[31]  RitaFacchetti,et al.  Visit-to-Visit Blood Pressure Variability, Carotid Atherosclerosis, and Cardiovascular Events in the European Lacidipine Study on Atherosclerosis , 2012 .

[32]  R. Collins,et al.  Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies , 2002, The Lancet.

[33]  Eoin O'Brien,et al.  Effects of β blockers and calcium-channel blockers on within-individual variability in blood pressure and risk of stroke , 2010, The Lancet Neurology.

[34]  H. Krum,et al.  Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial , 2010, The Lancet.

[35]  G. Mancia,et al.  When should antihypertensive drug treatment be initiated and to what levels should systolic blood pressure be lowered? A critical reappraisal , 2009, Journal of hypertension.

[36]  N J Wald,et al.  Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials , 2003, BMJ : British Medical Journal.

[37]  C. McCulloch,et al.  Elevated blood pressure and risk of end-stage renal disease in subjects without baseline kidney disease. , 2005, Archives of internal medicine.

[38]  M. Woodward,et al.  Prevalence, Awareness, Treatment, and Control of Hypertension in China: Data from the China National Nutrition and Health Survey 2002 , 2008, Circulation.

[39]  C. Reid,et al.  A comparison of outcomes with angiotensin-converting--enzyme inhibitors and diuretics for hypertension in the elderly. , 2003, The New England journal of medicine.

[40]  Kevin A Peterson,et al.  Effects of Intensive Blood-Pressure Control in Type 2 Diabetes Mellitus , 2011 .

[41]  Jiang He,et al.  Effects of Alcohol Reduction on Blood Pressure: A Meta-Analysis of Randomized Controlled Trials , 2001, Hypertension.

[42]  B. Sibai,et al.  Adverse perinatal outcomes are significantly higher in severe gestational hypertension than in mild preeclampsia. , 2002, American journal of obstetrics and gynecology.

[43]  Ramanan Laxminarayan,et al.  Disease Control Priorities in Developing Countries , 2013 .

[44]  J. Selby,et al.  Improving Blood Pressure Control Through a Clinical Pharmacist Outreach Program in Patients With Diabetes Mellitus in 2 High-Performing Health Systems: The Adherence and Intensification of Medications Cluster Randomized, Controlled Pragmatic Trial , 2012, Circulation.

[45]  C. McCulloch,et al.  Which Comes First—Renal Dysfunction or High Blood Pressure? Elevated Blood Pressure and Risk of End-Stage Renal Disease in Subjects without Baseline Kidney Disease. Arch Intern Med 165: 923–928, 2005 , 2005 .

[46]  K. Reynolds,et al.  Global burden of hypertension: analysis of worldwide data , 2005, The Lancet.

[47]  D. Magid,et al.  A Pharmacist-Led, American Heart Association Heart360 Web-Enabled Home Blood Pressure Monitoring Program , 2013, Circulation. Cardiovascular quality and outcomes.

[48]  Hilary K. Wall,et al.  National Surveillance Definitions for Hypertension Prevalence and Control Among Adults , 2012, Circulation. Cardiovascular quality and outcomes.

[49]  Daniel W. Jones,et al.  The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. , 2003, JAMA.

[50]  S. Yusuf,et al.  Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. , 2000 .

[51]  Heather M. Tavel,et al.  Incidence and Prognosis of Resistant Hypertension in Hypertensive Patients , 2012, Circulation.

[52]  W. Elliott.  Community-Based Interventions to Promote Blood Pressure Control in a Developing Country: A Cluster Randomized Trial , 2010 .

[53]  W. Elliott.  Blood Pressure Targets Recommended by Guidelines and Incidence of Cardiovascular and Renal Events in the Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial (ONTARGET) , 2012 .

[54]  Pascal Vranckx,et al.  Standardized endpoint definitions for Transcatheter Aortic Valve Implantation clinical trials: a consensus report from the Valve Academic Research Consortium. , 2011, Journal of the American College of Cardiology.

[55]  H. Krum,et al.  Renal sympathetic denervation for treatment of drug-resistant hypertension: one-year results from the Symplicity HTN-2 randomized, controlled trial. , 2012, Circulation.

[56]  A. Newman,et al.  Hypertension, White Matter Hyperintensities, and Concurrent Impairments in Mobility, Cognition, and Mood: The Cardiovascular Health Study , 2011, Circulation.

[57]  Karla Kerlikowske,et al.  Risks of untreated and treated isolated systolic hypertension in the elderly: meta-analysis of outcome trials , 2000, The Lancet.

[58]  Daniel W. Jones,et al.  Recommendations for blood pressure measurement in humans and experimental animals: Part 1: blood pressure measurement in humans: a statement for professionals from the Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research. , 2005, Hypertension.

[59]  Bill Bynum,et al.  Lancet , 2015, The Lancet.

[60]  S. Yusuf,et al.  Telmisartan, ramipril, or both in patients at high risk for vascular events. , 2008, The New England journal of medicine.

[61]  P. Mody,et al.  Trends in Antihypertensive Medication Use and Blood Pressure Control Among United States Adults with Hypertension : The National Health and Nutrition Examination Survey , 2001 to 2010 , 2022 .

[62]  Jing Chen,et al.  Prevalence, Awareness, Treatment, and Control of Hypertension in China , 2002, Hypertension.

[63]  Sudha Seshadri,et al.  Antecedent Blood Pressure and Risk of Cardiovascular Disease: The Framingham Heart Study , 2002, Circulation.

[64]  S. Lewington.  Prospective studies collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies (vol 360, pg 1903, 2002) , 2003 .

[65]  J. Curb,et al.  To what extent do cardiovascular risk factor values measured in elderly men represent their midlife values measured 25 years earlier? A preliminary report and commentary from the Honolulu Heart Program. , 1994, American journal of epidemiology.